{
    "type": "ETF",
    "ucits": true,
    "fund_name": "Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF",
    "investment_objective": "To track the performance before fees and expenses of the MSCI ACWI IMI Genomic Innovation Select Screened 100 Index, which reflects large, medium, and small-cap companies globally deriving significant revenues from genomic healthcare innovation.",
    "primary_asset_class": "Equity",
    "geographic_sector_focus": "Global equities with exposure to developed and emerging markets, focused on genomic healthcare innovation sector",
    "replication_method": "physical",
    "swaps": false,
    "derivatives": false,
    "leverage": false,
    "inverse": false,
    "complex_factors": [],
    "classification": "non-complex",
    "supporting_data": "The ETF uses physical replication by buying all or a substantial number of the securities in the index. The fund may use derivatives only for risk management purposes, not as an inherent part of the investment strategy, thus derivatives are marked false. There is no mention of synthetic replication, swap agreements, or counterparty risk exposure. The fund is UCITS compliant and invests directly in liquid equity securities. The risk profile is medium-high (5/7) due to sector concentration and emerging market exposure, but this does not imply complexity under MiFID II. No leverage, inverse or capital protection features are present. Costs are straightforward with a TER of 0.30%, no performance fees, and no swap or derivative fees. The index tracked is a screened thematic equity index with ESG criteria but does not involve complex structured products or contingent bonds. The PRIIPs KID does not carry any comprehension warnings or complexity flags. The factsheet confirms direct physical replication and no use of swaps or synthetic structures. Overall, the ETF exhibits a clear, linear relationship to the underlying index performance and invests in transparent, liquid equity securities without embedded leverage or complex derivative structures."
}